Through the whole-epigenome analysis of DNA methylation of CLL patients for the duration of treatment, it was found that enrichment for diverse CLL-specific epigenetic traits responded to chemotherapy that predict patient clinical outcomes, and especially involve epigenetic silencing of HOXA4 in decreasing the therapeutic sensitivity of CLL cells [38]. This evidence concerns the gene HOXA4 and B-cell chronic lymphocytic leukemia.